Target
ED-SCLC
1 abstract
Abstract
Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).Org: Kobe Minimally Invasive Cancer Center, Hakodate Goryoukaku Hospital, Fujita Health University Hospital, Onomichi General Hospital, Takarazuka City Hospital,